Ex Vivo Solutions for Radiopharmaceuticals
Rdcthera focuses on the delivery of preclinical CRO services in radiopharmaceutical development. Our ex vivo research solutions are extremely well-designed to help the development of radiopharmaceuticals by in-depth, accurate studies. At Rdcthera, we offer scientific, innovative solutions that have rigorous science backing them to make sure that the most advanced radiopharmaceuticals are brought to market by our tailored solutions in their development journey.
Ex Vivo Studies in Radiopharmaceutical Development
Such studies are very pivotal in the development of radiopharmaceuticals, whereby researchers have a controlled environment outside the living organism for examining the effects and interactions of the radiotracer. Information acquired from such studies is valuable for describing biodistribution, metabolism, and probable therapeutic actions of radiopharmaceuticals. The data accrued from ex vivo methods are very basic for the optimization of designs for radiotracers with a view to establishing their efficacy and safety prior to in vivo studies.
Fig. 1. Representative ex vivo images. (Taresco, et al., 2020)
Our Comprehensive Ex Vivo Solutions
Rdcthera offers ex vivo solutions to your specific needs in radiopharmaceutical preclinical research. The solutions are provided by well-versed scientists using up-to-date laboratory facilities to yield results in a reliable and reproducible manner. Therefore, the assays offer accurate testing of preclinical samples for the evaluation of new potential treatments - opportunity to find out elaborate results from a cellular and molecular level.
Our histology services provide detailed tissue analysis with sophisticated staining and imaging techniques. It enables research into the tissue distribution and cellular localization of radiopharmaceuticals, allowing for an explanation of their biodistribution and efficacy. Being fully equipped with advanced imaging systems and expertise, our state-of-the-art histology laboratory provides an exact and inclusive tissue assessment.
Learn More
Biomarkers are very vital indicators of biological processes and a drug's response to therapy. We offer biomarker identification and validation for specific biomarkers critical for radiopharmaceutical efficacy and safety assessment. Partner with us in the deployment of state-of-the-art technology to deliver accurate, informative biomarker analyses that drive drug development strategies.
Learn More
Flow cytometry is among the most important tools in cellular characteristic and population analysis. Using our flow cytometry services, we can gain far-reaching information on cellular interactions and immune responses elicited by radiopharmaceuticals. We offer high-resolution analyses supporting the development of targeted therapies.
Learn More
We offer microbiome analysis services to study interactions between radiopharmaceuticals and microbial communities and provide insights into drug development and optimization. Our team can deliver such complete profiles of the microbiome by the most advanced sequencing and analytics techniques.
Learn More
Radiopharmaceutical metabolism is comprehended in its entirety for optimizing design and applications. Our radiometabolite analysis services enable detailed studies regarding radiotracer metabolism, thereby allowing insight into their stability, breakdown, and clearance. All this information can be very critical in developing an effective and safe radiopharmaceutical.
Learn More
Customized Solutions for Specialized Needs
Rdcthera understands quite well that every research project is different from the rest. We offer customized ex vivo solutions according to study needs and specific research objectives. Our team works closely with clients in developing a study design tailored to answer particular scientific questions and challenges.
Why Choose Rdcthera?
To learn more about how Rdcthera can support your radiopharmaceutical development through our ex vivo research services, please contact us today. At Rdcthera, we are committed to helping you achieve your research goals with precision and excellence.
Reference
- Taresco, Vincenzo & Abelha, Thais & Cavanagh, et al. (2020). Functionalized Block Co-Polymer Pro‐Drug Nanoparticles with Anti-Cancer Efficacy in 3D Spheroids and in an Orthotopic Triple Negative Breast Cancer Model. Advanced Therapeutics. 4. 10.1002/adtp.202000103.
For research use only. Not intended for any clinical use.
Related Service
